Encouragingly, sotrastaurin has recently been shown to display selective cytotoxicity towards CLL cells and can inhibit their proliferation by altering the BCR-dependant survival pathways (MAPK, PI3K and NF-κB). The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.